Fmr LLC raised its position in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 5.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,145,056 shares of the company’s stock after acquiring an additional 2,593,910 shares during the quarter. Fmr LLC owned approximately 6.65% of Roivant Sciences worth $567,134,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in ROIV. Rubric Capital Management LP lifted its stake in Roivant Sciences by 15.0% in the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after acquiring an additional 3,000,000 shares during the last quarter. Troluce Capital Advisors LLC acquired a new stake in Roivant Sciences in the second quarter valued at $31,182,000. BlackBarn Capital Partners LP lifted its stake in Roivant Sciences by 63.1% in the second quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company’s stock valued at $32,767,000 after acquiring an additional 1,199,406 shares during the last quarter. Vanguard Group Inc. lifted its stake in Roivant Sciences by 14.6% in the first quarter. Vanguard Group Inc. now owns 8,106,332 shares of the company’s stock valued at $85,441,000 after acquiring an additional 1,030,681 shares during the last quarter. Finally, Sofinnova Investments Inc. lifted its stake in shares of Roivant Sciences by 86.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,868,412 shares of the company’s stock worth $19,749,000 after buying an additional 866,708 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.
Roivant Sciences Stock Performance
NASDAQ:ROIV opened at $12.69 on Friday. Roivant Sciences Ltd. has a 52 week low of $8.87 and a 52 week high of $13.06. The firm has a market cap of $9.24 billion, a price-to-earnings ratio of 2.25 and a beta of 1.24. The firm’s 50-day simple moving average is $11.75 and its 200 day simple moving average is $11.37.
Insider Buying and Selling
Analysts Set New Price Targets
A number of research firms have recently issued reports on ROIV. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. Bank of America raised their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $17.93.
Check Out Our Latest Stock Analysis on Roivant Sciences
Roivant Sciences Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
- Five stocks we like better than Roivant Sciences
- The 3 Best Blue-Chip Stocks to Buy Now
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- How to Use High Beta Stocks to Maximize Your Investing Profits
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How to Start Investing in Real Estate
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.